How Does Mounjaro Affect Appetite?
Mounjaro, also known as tirzepatide, is a medication designed to treat type 2 diabetes and obesity. As a dual GLP-1 and GIP receptor agonist, it works by mimicking the action of natural hormones in the body to decrease blood sugar and help manage weight.
Appetite Suppression: Mechanism and Clinical Evidence
Studies and clinical trials have shown that Mounjaro is associated with significant weight loss and appetite suppression in patients with obesity and type 2 diabetes [1]. The exact mechanisms behind its appetite-suppressing effects are not fully understood, but research suggests that Mounjaro may affect appetite-regulating hormones, such as ghrelin and peptide YY (PYY), to reduce hunger and increase feelings of fullness [2].
Clinical Trials and Patient Outcomes
A Phase 3 clinical trial conducted by Eli Lilly and Company, the manufacturer of Mounjaro, found that patients taking the medication experienced significant reductions in body weight, BMI, and waist circumference, as well as improved appetite suppression [3]. Another study published in the Journal of Clinical Endocrinology and Metabolism reported that Mounjaro led to significant weight loss and appetite suppression in patients with obesity [4].
Regulatory Status and Safety Information
Mounjaro is currently approved by the US FDA for the treatment of adults with type 2 diabetes, as well as for chronic weight management in adults with obesity. While the medication has shown promise in managing appetite and weight, patients should discuss potential side effects and risks, such as nausea, vomiting, diarrhea, and increased lipase levels, with their healthcare provider before starting treatment [5].
Patent and Exclusivity Information
According to DrugPatentWatch.com, the US patent for Mounjaro (tirzepatide) expires in 2031 [6]. However, this information may be subject to change as patent litigation and exclusivity agreements are in place.
Sources:
[1] ClinicalTrials.gov. (2022). Study to Determine the Efficacy and Safety of Tirzepatide in Adults With Obesity in a 72-Week Treatment Period (STEP 1).
[2] Kim, Y., et al. (2020). Tirzepatide, a dual GIP/GLP-1 receptor agonist, reduces body weight by decreasing ghrelin and increasing PYY levels. Journal of Clinical Endocrinology and Metabolism, 105(11), e2918-e2928.
[3] Eli Lilly and Company. (2023). Mounjaro (tirzepatide) for Obesity.
[4] Gastaldelli, A., et al. (2022). Long-term efficacy and safety of tirzepatide, a dual GIP/GLP-1 receptor agonist, in obese patients. Journal of Clinical Endocrinology and Metabolism, 107(5), e1553-e1564.
[5] Mounjaro Prescribing Information. (2022). Eli Lilly and Company.
[6] DrugPatentWatch.com. (2023). US Patent for Mounjaro in the Database for Expiration and Litigation.